Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA Vaccine for HBV-positive Advanced HCC
NCT05738447Phase 1Unknown
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2023
- Primary completion
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HBV mRNA vaccine in hepatocellular carcinoma (HCC), sponsored by West China Hospital of Sichuan University. Primary endpoints: Adverse events up to 12 months, Objective response rate up to 12 months and 2 more. Status: unknown.
02
Drugs
HBV mRNA vaccine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05738447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05738447.